A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (IVY)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02009449 |
Recruitment Status :
Active, not recruiting
First Posted : December 12, 2013
Last Update Posted : January 24, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Melanoma Prostate Cancer Ovarian Cancer Renal Cell Carcinoma Colorectal Carcinoma Pancreatic Carcinoma Non-small Cell Lung Carcinoma Solid Tumors Breast Cancer | Drug: Pegilodecakin Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) Drug: gemcitabine/nab-paclitaxel Drug: Capecitabine Drug: Pazopanib Drug: Pembrolizumab Drug: Paclitaxel Drug: nivolumab Drug: Gemcitabine/carboplatin | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 350 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors |
Actual Study Start Date : | November 15, 2013 |
Actual Primary Completion Date : | February 19, 2019 |
Estimated Study Completion Date : | August 25, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Part A: Dose Escalation Cohort 1
Pegilodecakin (1 ug/kg) - Daily subcutaneous (SC) injections of pegilodecakin for up to 22 months
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
|
Experimental: Part A: Dose Escalation Cohort 2
Pegilodecakin (2.5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
|
Experimental: Part A: Dose Escalation Cohort 3
Pegilodecakin (5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
|
Experimental: Part A: Dose Escalation Cohort 4
Pegilodecakin (10 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
|
Experimental: Part A: Dose Escalation Cohort 5
Pegilodecakin (20 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
|
Experimental: Part A: Dose Escalation Cohort 6
Pegilodecakin (40 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
|
Experimental: Part A: Dose Expansion Cohort 1
at least 15 RCC participants will be dosed with pegilodecakin for up to 22 months
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
|
Experimental: Part B: Dose Escalation Cohort 1
Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles. Day 1
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin Day 1 of every 21 day cycle
Other Name: Taxol or taxotere and paraplatin or platinol |
Experimental: Part B: Dose Escalation Cohort 2
Pegilodecakin (5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles. Day 1
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin Day 1 of every 21 day cycle
Other Name: Taxol or taxotere and paraplatin or platinol |
Experimental: Part B: Dose Escalation Cohort 3
Pegilodecakin (10 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles. Day 1
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin Day 1 of every 21 day cycle
Other Name: Taxol or taxotere and paraplatin or platinol |
Experimental: Part B: Dose Expansion Cohort
Daily SC injection with pegilodecakin with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles. Day 1
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin Day 1 of every 21 day cycle
Other Name: Taxol or taxotere and paraplatin or platinol |
Experimental: Part C: Dose Escalation Cohort 1
Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ; Day 1
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) Intravenous administration on Day 1 and 2 of every 14 day cycle
Other Name: Eloxatin®/Leucovorin/5-FU |
Experimental: Part C: Dose Escalation Cohort 2
Pegilodecakin (5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ; Day 1
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) Intravenous administration on Day 1 and 2 of every 14 day cycle
Other Name: Eloxatin®/Leucovorin/5-FU |
Experimental: Part C: Dose Escalation Cohort 3
Pegilodecakin (10 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ; Day 1
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) Intravenous administration on Day 1 and 2 of every 14 day cycle
Other Name: Eloxatin®/Leucovorin/5-FU |
Experimental: Part C: Dose Expansion Cohort 1
Daily SC injection with pegilodecakin with FOLFOX4 Every 14 days FOLFOX4; (14 days = 1 cycle) ; Day 1
|
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) Intravenous administration on Day 1 and 2 of every 14 day cycle
Other Name: Eloxatin®/Leucovorin/5-FU |
Experimental: Part D: Dose Escalation Cohort 1
Pegilodecakin (5 ug/kg) daily subcutaneous injections with Gemcitabine and nab-paclitaxel on Days 1, 8, 15 of each cycle (28 days = 1 cycle). Nab-paclitaxel 125 mg/m2 IV over 30 minutes followed by • Gemcitabine 1000 mg/m2 IV. |
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: gemcitabine/nab-paclitaxel Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.
Other Name: Gemzar/Abraxane ABI-007 |
Experimental: Part E: Dose Escalation Cohort 1
Pegilodecakin (10 ug/kg) daily subcutaneous injections with capecitabine BID daily for 14 days of each cycle (21 days= 1 cycle). • Capecitabine 1000 mg/m2 po BID |
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: Capecitabine Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
Other Name: Xeloda |
Experimental: Part F: Dose Escalation Cohort 1
Pegilodecakin (10 ug/kg) daily subcutaneous injections with paclitaxel on Days 1, 8, 15 of each cycle (28 days= 1 cycle) • Paclitaxel 80 mg/ m2 IV |
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: Paclitaxel Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle) • Paclitaxel 80 mg/ m2 IV |
Experimental: Part G: Dose Escalation Cohort 1
Pegilodecakin (10 ug/kg) daily subcutaneous injections with pazopanib orally given daily for 14 days of each cycle (21 days= 1 cycle) • Pazopanib 800 mg po QD |
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: Pazopanib Pazopanib will be administered orally daily continuously
Other Name: GW786034 |
Experimental: Part H: Dose Escalation Cohort 1
Pegilodecakin (10 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle). • Pembrolizumab 2 mg/kg IV over 30 min |
Drug: Pegilodecakin
Daily subcutaneous injections of pegilodecakin up to 12 months
Other Names:
Drug: Pembrolizumab Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
Other Name: Keytruda, MK-3475 |
Experimental: Part I: Dose Escalation Cohort 1
Pegilodecakin (20 ug/kg) daily subcutaneous injections with nivolumab on Day 1 of each cycle (14 days= 1 cycle). • Nivolumab 3 mg/kg IV over 60 min |
Drug: nivolumab
Nivolumab on Day 1 of each cycle (14 days = 1 cycle)
Other Name: Keytruda |
Experimental: Part H: Dose Escalation Cohort 2
Pegilodecakin (20 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle). • Pembrolizumab 2 mg/kg IV over 30 min |
Drug: Pembrolizumab
Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
Other Name: Keytruda, MK-3475 |
Experimental: Part H: Dose Escalation Cohort 3
Pegilodecakin (40 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle). • Pembrolizumab 2 mg/kg IV over 30 min |
Drug: Pembrolizumab
Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
Other Name: Keytruda, MK-3475 |
Experimental: Part J: Dose Escalation Cohort 1
Pegilodecakin (10 ug/kg) daily subcutaneous injections with gemcitabine and carbolplatin on Days 1,8 of each cycle (21 days=1 cycle) until disease progression gemcitabine 1000mg/m2 IV over 30 minutes followed by carboplatin AUC2 over 60 minutes
|
Drug: Gemcitabine/carboplatin
gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)
Other Name: gemzar/paraplatin |
- Safety and tolerability as measured by incidence of adverse events [ Time Frame: up to 12 months ]
- Pharmacokinetic (PK) parameters [ Time Frame: up to 12 months ]PK parameters including the serum trough concentration (Minimal Drug Concentration (Cmin)), the maximal drug concentration (Cmax), area under the curve of serum concentration over time (Area Under the Curve/ AUC), and half-life (t½).
- Change in tumor burden measured by volumetric Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) according to immune-related response criteria (irRC) [ Time Frame: up to 12 months ]
- Progression in bone by bone scintigraphy according to Prostate Cancer Working Group 2 (PCWG2) for participants with metastatic castration resistant prostate cancer (CRPC) [ Time Frame: approximatley 4 months ]
- Anti-Pegilodecakin antibody formation [ Time Frame: up to 12 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Part A Escalation Cohorts:
o Histologically or cytologically confirmed advanced malignant solid tumor, limited to melanoma, castrate resistant prostate cancer (CRPC), ovarian cancer (OVCA), renal cell carcinoma, colorectal carcinoma (CRC), pancreatic carcinoma or non-small cell lung carcinoma (NSCLC) that is refractory to, intolerant of, for which no standard of therapy is available or where the participant refuses existing therapies
Part A Expansion Cohorts, Part B and C Escalation and Expansion Cohorts:
- Tumors with all histological diagnosis or tissue origin may be enrolled
-
Participants must have failed prior standard curative chemotherapy for their disease, refuse existing therapies OR the proposed chemotherapy regimen to which pegilodecakin is added represents an acceptable standard treatment for their disease.
- Measurable or evaluable disease according to irRC or bone metastatic disease evaluable by Prostate Cancer Working Group 2 criteria (PCWG2) for castration-resistant prostate cancer (CRPC)
- At least 18 years of age
- Performance Status of 0 or 1
- Adequate organ function
Exclusion Criteria:
- Hematologic malignancies
- Pregnant or lactating
- Present or history of neurological disorders such as Multiple Sclerosis and Guillain Barre or inflammatory central nervous system/peripheral nervous system (CNS/PNS) disorders
- Myocardial infarction within the last 6 months
- Unstable angina, or unstable cardiac arrhythmia requiring medication
- Surgery within the last 28 days
- Systemic fungal, bacterial, viral, or other infection
- History of bleeding diathesis within the last 6 months
- Positive for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02009449
United States, California | |
UCLA Medical Hematology & Oncology | |
Los Angeles, California, United States, 90024 | |
UCSF | |
San Francisco, California, United States | |
United States, Colorado | |
Sarah Cannon Research Institute at HealthONE | |
Denver, Colorado, United States, 80218 | |
United States, Florida | |
Florida Cancer Specialists & Research Institute | |
Sarasota, Florida, United States, 34232 | |
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 | |
United States, New York | |
Memorial Sloan Kettering Cancer Center | |
New York, New York, United States, 10065 | |
United States, Oklahoma | |
Stephenson Cancer Center at Oklahoma University TSET Phase 1 Program | |
Oklahoma City, Oklahoma, United States, 73104 | |
United States, Tennessee | |
Sarah Cannon Research Institute | |
Nashville, Tennessee, United States, 37203 | |
United States, Texas | |
The University of Texas M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
South Texas Accelerated Research Therapeutics | |
San Antonio, Texas, United States, 78229 |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Responsible Party: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT02009449 |
Other Study ID Numbers: |
17159 J1L-AM-JZGA ( Other Identifier: Eli Lilly and Company ) AM0010-001 ( Other Identifier: ARMO BioSciences ) |
First Posted: | December 12, 2013 Key Record Dates |
Last Update Posted: | January 24, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Phase 1/Phase 1b Oncology Cancer Solid Tumors |
Carcinoma Carcinoma, Renal Cell Colorectal Neoplasms Carcinoma, Non-Small-Cell Lung Pancreatic Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Urogenital Neoplasms Neoplasms by Site Urogenital Diseases Male Urogenital Diseases Endocrine Gland Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications |
Endocrine System Diseases Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Kidney Diseases Urologic Diseases Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Lung Diseases Respiratory Tract Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases |